ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-Tcell
globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label,
multicentre phase 3 trial

Bethge WA Finke J; Jorge Sierra Gil

ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-Tcell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

Departament de Medicina

Producció científica: Contribució a revista › Article › Recerca

Idioma original	Anglès
Pàgines (de-a)	855-864
Revista	Lancet Oncol
Volum	10
Número	9
Estat de la publicació	Publicada - 1 de gen. 2009

Altres arxius i enllaços

https://www.scopus.com/pages/publications/69249193742

Com citar-ho

@article{d28d832b69714c81b0829bcfa4215963,

title = "ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-Tcell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial",

author = "\{Finke J\}, \{Bethge WA\} and \{Sierra Gil\}, Jorge",

year = "2009",

month = jan,

day = "1",

language = "English",

volume = "10",

pages = "855--864",

number = "9",

}

ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-Tcell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. / Finke J, Bethge WA; Sierra Gil, Jorge.
In: Lancet Oncol, Vol. 10, Núm. 9, 01.01.2009, pàg. 855-864.

Producció científica: Contribució a revista › Article › Recerca

TY - JOUR

T1 - ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-Tcell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial

AU - Finke J, Bethge WA

AU - Sierra Gil, Jorge

PY - 2009/1/1

Y1 - 2009/1/1

UR - https://www.scopus.com/pages/publications/69249193742

M3 - Article

SN - 1470-2045

VL - 10

SP - 855

EP - 864

JO - Lancet Oncol

JF - Lancet Oncol

IS - 9

ER -